Disease · MONDO_0005098
Comparisons in its trials90
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 90
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 | 2,524 of 163,812 | 327,624 | NCT03817463 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,095 of 7,796 | 1,272 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,061 of 7,796 | 2,393 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,110 of 7,796 | 1,283 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 24 Months: Secondary Prevention (Balanced) Cohorts | 850 of 7,796 | 1,028 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 24 Months: Secondary Prevention (Balanced) Cohorts | 845 of 7,796 | 1,024 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,426 of 7,796 | 1,670 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,448 of 7,796 | 1,685 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,081 of 7,796 | 2,412 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With BARC Type 2, 3, or 5 | 141 of 3,555 | 250 of 3,564 | 7,119 | NCT02270242 | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: serious adverse events | 262 of 3,555 | 370 of 3,564 | 7,119 | NCT02270242 | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With Ischemic Episode | 135 of 3,524 | 137 of 3,515 | 7,039 | NCT02270242 | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: deaths from any cause | 34 of 3,524 | 45 of 3,515 | 7,039 | NCT02270242 | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event | 262 of 2,641 | 269 of 2,635 | 5,276 | NCT01742117 | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding | 54 of 2,641 | 53 of 2,635 | 5,276 | NCT01742117 | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: deaths from any cause | 95 of 2,641 | 98 of 2,635 | 5,276 | NCT01742117 | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: serious adverse events | 0 of 2,641 | 0 of 2,635 | 5,276 | NCT01742117 | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 35 of 903 | 54 of 946 | 1,849 | NCT01742117 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005098/comparisons